Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18230 ↗At a glance
Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2024. Written by María Chaparro and 59 co-authors. Institution: Gastrointestinal Units of Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma d…. Major MEDLINE topics: Ustekinumab, Colitis, Ulcerative. Cited 4 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Janssen Pharmaceuticals, Janssen Pharmaceutica.
Abstract (original language)
Background
Ustekinumab is approved for ulcerative colitis (UC).
Aims
To assess the durability of ustekinumab in patients with UC and its short‐term effectiveness, durability and tolerability in clinical practice.
Methods
Retrospective, multicentre study of patients who had received their first ustekinumab dose at least 16 weeks before inclusion. Patients were followed until treatment discontinuation or last visit. Only patients with active disease at the start of ustekinumab treatment were considered in the effectiveness analysis. Patients who stopped ustekinumab before their last visit were considered not to be in subsequent remission.
Results
We included 620 patients; 155 (25%) discontinued ustekinumab during follow‐up (median 12 months). Rate of discontinuation was 20% per patient‐year of follow‐up. Anaemia at baseline (hazard ratio, HR 1.5; 95% confidence interval [CI] 1.1–2.1), steroids at baseline (HR 1.5; 95% CI 1.06–2.08) and more severe clinical activity at baseline (HR 1.5; 95% CI 1.09–2.06) were associated with higher risk of discontinuation. At the end of induction, 226 (40%) patients were in steroid‐free clinical remission. Moderate–severe vs mild disease activity at baseline (odds ratio [OR] 0.3; 95% CI 0.2–0.5), male sex (OR 0.5; 95% CI 0.4–0.8), and increased number of previous biologics (OR 0.6; 95% CI 0.6–0.8) were associated with lower likelihood of steroid‐free clinical remission at week 16. One hundred and seventy‐six patients (28%) had at least one adverse event. We observed no negative impact of ustekinumab on extraintestinal manifestations and/or immune‐mediated diseases.
Conclusions
Ustekinumab durability in UC was relatively high, and treatment was effective in highly refractory patients. The safety profile was consistent with previous studies.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Gastrointestinal Units of Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedad…
- Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and CIBEREHD, Barcelona, Spain.
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
- Hospital Universitario Torrecárdenas, Almería, Spain.
- Hospital Clínico Universitario Lozano Blesa and Fundación del Instituto de Investigación Sanitaria de Aragón (IIS Aragón) and CIBEREHD, Zaragoza, Spain.
- Hospital Clínico Universitario de Valencia, Valencia, Spain.
ORCID profiles: María Chaparro, Agnès Fernández-Clotet, Marta Maia Bosca-Watts, Sabino Riestra, Xavier Calvet, José María Huguet, Ángel Ponferrada-Díaz, Ana Gutiérrez Casbas
Funding
- Janssen Pharmaceuticals
- Janssen Pharmaceutica
Cite
APA
Chaparro, M., Hermida, S., Acosta, D., Fernández-Clotet, A., Barreiro-de Acosta, M., Hernández Martínez, Á., Arroyo, M., Bosca-Watts, M. M., Diz-Lois Palomares, M. T., Menchén, L., Martínez Cadilla, J., Leo-Carnerero, E., Muñoz Villafranca, C., Sierra-Ausín, M., González-Lama, Y., Riestra, S., Sendra Rumbeu, P., Cabello Tapia, M. J., García de la Filia, I., …, & Rubio Mateos, J. M. (2024). Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18230
Vancouver
Chaparro M, Hermida S, Acosta D, Fernández-Clotet A, Barreiro-de Acosta M, Hernández Martínez Á, et al. Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18230
BibTeX
@article{Chaparro2024,
author = {Chaparro, María and Hermida, Sandra and Acosta, Diana and Fernández-Clotet, Agnès and Barreiro-de Acosta, Manuel and Hernández Martínez, Álvaro and Arroyo, Maite and Bosca-Watts, Marta Maia and Diz-Lois Palomares, M Teresa and Menchén, Luis and Martínez Cadilla, Jesús and Leo-Carnerero, Eduardo and Muñoz Villafranca, Carmen and Sierra-Ausín, Mónica and González-Lama, Yago and Riestra, Sabino and Sendra Rumbeu, Pau and Cabello Tapia, M José and García de la Filia, Irene and Vicente, Raquel and Ceballos, Daniel and Pajares Villarroya, Ramón and Ramírez de la Piscina, Patricia and Martín-Arranz, María Dolores and Ramos, Laura and Ruiz-Cerulla, Alexandra and Martínez-Pérez, Teresa de Jesús and San Miguel Amelivia, Elena and Calvet, Xavier and Huguet, José María and Keco-Huerga, Alma and Lorente Poyatos, Rufo H and Muñoz, José Fernando and Ponferrada-Díaz, Ángel and Sicilia, Beatriz and Delgado-Guillena, Pedro and Gómez Delgado, Elena and Rancel-Medina, Francisco J and Alonso-Galán, Horacio and Herreros, Belén and Rivero, Montserrat and Varela, Pilar and Bermejo, Fernando and García Sepulcre, Marifé and Gimeno-Pitarch, Leticia and Kolle-Casso, Lilyan and Márquez-Mosquera, Lucía and Martínez Tirado, Pilar and Ramírez, Cynthia and Sesé Abizanda, Eva and Dueñas Sadornil, Carmen and Fernández Rosáenz, Hipólito and Gutiérrez Casbas, Ana and Madrigal Domínguez, Rosa Eva and Nantes Castillejo, Óscar and Ber Nieto, Yolanda and Botella Mateu, Belén and Frago Larramona, Santiago and López Serrano, Pilar and Rubio Mateos, José María},
title = {Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18230}
}
EUVIMED